Dermata Therapeutics, Inc. (DRMA) Operating cash flow 2021–2026
Dermata Therapeutics, Inc. (DRMA) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$7.8MFY2026 · since FY2021: -$4.0M → -$7.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$7.8M | +30.1% |
| FY2025 | -$11.2M | -74.2% |
| FY2024 | -$6.4M | +27.5% |
| FY2023 | -$8.8M | -55.2% |
| FY2022 | -$5.7M | -41.3% |
| FY2021 | -$4.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More DRMA financial trends
DRMA RevenueDRMA Net incomeDRMA Net marginDRMA Gross profitDRMA Gross marginDRMA Operating incomeDRMA Operating marginDRMA Free cash flowDRMA Capital expendituresDRMA Return on equityDRMA Stock buybacksDRMA Dividends paidDRMA Total assetsDRMA Total liabilitiesDRMA Shareholders’ equityDRMA overview →